Aquestive Therapeutics is trading 5.01% lower at $3.69, with no confirmed cause identified for the November 2 decline. - Q3 results are scheduled for November 3 after market close; the report is upcoming, not an explanation for the move. - Major indexes were higher in the supplied market context, so the stock’s decline did not appear to track the broader-market rebound.